In the specific context of ICB treatment, one study in 85 patients with hepatocellular carcinoma (HCC) treated with the combination of PD-L1 and anti-vascular endothelial growth factor (VEGF) inhibitors established a correlation of plasma cfDNA levels with response and progression-free and overall survival [24]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.